Advanced Bifurcation Selected to Join MaRs Venture Services
Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced that ABS, through its wholly-owned Canadian subsidiary, Advanced Bifurcation Systems Canada, Inc. (“ABS Canada”) has been selected to join MaRS Venture Services.
MaRS Venture Services helps high-impact, growth-ready ventures succeed. MaRS works with over 1,000 innovative ventures in Canada, with the goal of turning breakthrough ideas into successful, global companies. The MaRS Discovery District in Toronto is one of the world's largest urban innovation hubs. One of MaRS four main sectors is Health, with the MaRS strategy being to improve health outcomes by building high-impact, high-growth ventures and innovative health ecosystems.
The ABS platform, which can substantially improve cardiac health outcomes in the treatment of bifurcation lesions in coronary angioplasties (a US$2.5 billion global market) matches perfectly to the MaRS strategy.
“We are delighted to become a member of the MaRS Venture Services community. This involvement should help us to accelerate ABS’s regulatory approval process, clinical trials completion and, ultimately, product access into the Canadian healthcare system, which serves 35 million patients,” said Charles Laverty, CEO of Advanced Bifurcation Systems.
“The Canadian healthcare innovation market is very robust, and Canada is becoming a global leader in healthcare innovation. We intend to capitalize upon the many resources, and cost savings, available in Canada for companies like ABS,” commented Ken Richards, CFO of ABS.
Separately, the Company announced that it had secured the trademarks for ABS (Advanced Bifurcation Systems) and ABS Mother-Daughter which visually illustrates the unique patented platform technology that has been developed for the treatment of bifurcation lesions in coronary angioplasties.
About Advanced Bifurcation Systems
Advanced Bifurcation Systems (“ABS”) is a clinical stage medical device company developing an innovative stenting platform for simple treatment of all bifurcation lesions in coronary angioplasties. ABS has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure. The Company’s groundbreaking system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting as well as full bifurcation stenting with a proprietary crimping technology allowing for partial crimping of the main stent. For more information, go to www.advancedbifurcation.com.
Advanced Bifurcation Systems
Chief Executive Officer